All News

Patents could provide intellectual property protection for Alimta in Japan until June 2021.

First anti-PD-1 therapy approved in Europe for previously untreated patients with metastatic NSCLC.

The Dublin offices are the company's first permanent business premises outside of North America.

Patent found to be invalid.

Acquisition creates world-class aesthetic and regenerative medicine business in plastic surgery.

Bioverativ common stock to be traded on the NASDAQ global select market.

Xyzal is an oral antihistamine with a proven 24-hour effect.

Regulatory decisions for Kevzara are anticipated in the US and European Union later this year.

Decision marks the third TSC-related indication for Votubia in the EU.

Patents in question invalidated based on obviousness.

The enlarged business will comprise 21 manufacturing centres and commercial operations across 60 countries.

Manufacturing projects in eco-friendly and biodegradable packaging, which is expected to surge in near future.

New perfeXion system, which generates around 100,000 data tags/min, makes an important contribution to quality assurance for downstream post-processing steps at the beginning of the value chain.

Marken has successfully completed shipments originating from Mount Everest as part of an important research program designed to study the effects of high altitude on the human body. 

Developments in local manufacturing, regulatory strategies, market entry and harmonisation to be debated by MENA leaders and Government.

Effectively handles difficult-to-mix pharmaceutical ingredients.

New clinical data for Avycaz demonstrates efficacy in cUTI patients including those with infections due to resistant Gram-negative pathogens.

First treatment approved in 5 years for adolescents aged 13-17 years with schizophrenia.

Amgen receives positive CHMP opinion for biosimilar adalimumab.

Actelion R&D unit to spin out into standalone company based and listed in Switzerland.

Combination studied as treatment for patients with advanced clear cell renal cell carcinoma.

Issued claims are directed to a series of orally available small molecules and their use in treating epilepsy, neuropathic pain, and other neurological disorders.

New dosage strength expected to be available in first quarter of 2017.

Company expects to invest cost savings in its branded and generics business segments.

AnestaGel uses a novel approach to delivering sustained-released analgesics into the target tissue via the Matrix, which is a tunable, biocompatible, and pH neutral platform.

Clinical trial is the first of its kind to treat IBS symptoms by cannabinoid-containing chewing gum.

Disease prevalence can be monitored with a precision never before possible.

Provides the company with increased control over discovery research, antibody generation, medicinal chemistry and bioconjugation for generating antibody drug conjugates.

GenVec's AdenoVerse to be integrated into Intrexon's proprietary synthetic biology platform.

Investments include an LC-MS/MS, and GC-MS with head-space capability, for improved and rapid identification of trace unknown extractable compounds.

Site enlargement enables increased capacity for state-of-the-art quality control and storage.

VR647 is a drug/device combination, using the AKITA JET smart nebuliser, for the delivery of nebulised budesonide.

Feasibility study to examine three different oral formulations engineered with Enteris’ Peptelligence platform.

Extends multi-year agreement in drug discovery with focus on cardiovascular and central nervous system disorders, immunology, infectious diseases and oncology.

The first chemically-defined, animal component-free, cell culture medium for T cells.

The molecule, which is a PPMO, will likely be ready for testing in humans in about 3 years.

No admission of wrongdoing, No monetary payment by Endo.

Merck to pay BMS and Ono royalties on global sales of Keytruda through 2026, and lump-sum payment of $625 million.

Topline results from the Phase II trial are expected by year-end 2017.

Sofosbuvir/Velpatasvir/Voxilaprevir cranted an accelerated assessment by the EMA.

Cold-EEZE will become Mylan's largest US OTC brand franchise.

Once-daily treatment reduces persistent facial erythema associated with rosacea through 12 hours.

Opdivo demonstrated a 37% reduction in the risk of death compared to placebo.

Getting the most out of punches and dies with a simple and powerful tooling management system.

Collaboration between pharma and biotech underscores potential for new approaches to partnering.

Unique technology portfolio enables design space characterization, effective translation to the large-scale and enhanced process analytics.

Deal will enhance Lilly's existing pain management portfolio for migraine and adds potential near-term launch to its late-stage pipeline.

Company's subsidiary currently involved in patent litigation concerning this product.

The South East Asia exhibition now includes Investment Forum, Roadshows and Business Matchmaking.

Regulatory compliant, FDA-audited facility based in Mollet des Vallès, Spain.

The settlement and license agreement will strengthen Biogen's IP for leading oral therapy for multiple sclerosis.

Therapies targeted at this novel mechanism have the potential for disease-modification because they will address the genetic root cause of AD.

Suliqua will be delivered in two pre-filled SoloSTAR pens, providing different dosing options that may help answer individual market and patient insulin needs.

Opiorphin represents a new class of potent and safe painkiller.

leon nanodrugs' MJR technology offers reformulation options that address API solubility issues.

WHF therapy can be directly applied on a wound to stimulate the natural human wound healing process.

Transaction includes US commercialization rights for Onivyde for metastatic pancreatic cancer in adult patients.

No concerns raised by FDA related to the rolapitant IV efficacy or safety profile and additional clinical studies are not required.

Rising demand for all categories of medicines, especially generic drugs.

Novo Nordisk to launch Fiasp in first half of 2017.

Product receives designations for both the BV treatment and prevention indications.

Comprehensive validation services for the Chinese market.

All programs (two promising clinical-stage programs targeting DNA damage and repair, and two novel pre-clinical programs) have first-in-class and best-in-class potential.

RHB-104 is a proprietary and potentially groundbreaking antibiotic combination therapy in oral capsule formulation.

If the patent is ultimately upheld through all remaining challenges, Alimta would maintain US exclusivity until May 2022.

If approved, MYL-1401O has potential to be the first biosimilar trastuzumab in the US.

New study to evaluate combination of Lartruvo and Keytruda.

Company aims to increase production capacity to supply multiple commercial-scale therapeutic vaccines under development.

Collaboration will give Pierre Fabre the option to enter into exclusive negotiations to license global rights for the program in selected skin cancer conditions.

Expansionincludes the opening of two new process development centers in the US and China.

Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities.

Scientists can confirm, in one easy step, whether an antibody has been successfully conjugated.

Generis is the most sold pharmaceutical brand in Portugal, and is the #2 generic group in Portugal.

Deal expands Allergan's innovative GI [ipeline with ABI-M201 and ABI-M301, preclinical compounds targeting Uucerative colitis and Crohn's disease, as well as future compounds for irritable bowel syndrome.

KumaMax could provide hope celiac patients who try, but are unable to completely avoid gluten exposure in their diets,

JOTROL is being developed to remedy resveratrol’s poor bioavailability and dose limiting gastrointestinal side effects.

Company collaborating with all participants in the pharma supply chain to tackle to the epidemic of prescription drug abuse.

Ariad stockholders to receive $24.00 per share in cash.

A ready-to-use, stable and soluble, parenteral form of clopidogrel is feasible using the company's nanoemulsion platform technology.

Christi Shaw hired to lead Bio-Medicines; Conterno to assume additional geographic responsibilities, including Lilly USA leadership; Zulueta to lead International business.

Phase Ib/II studies to explore a novel immuno-oncology combination in hematological and solid tumours with high unmet medical need.

Noxxon continues transition to clinical oncology company.

The company's long-acting therapeutic peptides are designed to allow the efficient delivery of the active element to intracellular targets.

PolyPeptide Laboratories' acquisition brings immediate access to additional large-scale capacity in synthesis, purification and isolation of peptides.

Application seeks to extend duration of use up to 4 years for Liletta.

Concordia will continue to be responsible for the manufacturing and supply of Donnatal in all territories.

Appointment of Ian Clark as Non-Executive Director.

Website allows visitors to simply and quickly locate pertinent information.

Presentation provides new data regarding the mechanism of the ControLyo Technology.

Each company will separately pursue their own vaccine strategies in Europe.

Resunab is designed to resolve inflammation thus having the potential to provide significant clinical benefit to CF patients, importantly without immunosuppression.

Reported research continues to demonstrate the anti-cancer properties of cannabinoids.

Pharmaserv Logistics, which specialises in pharmaceutical logistics, temperature-controlled exports and pre-wholesale solutions, has concluded a contract with vaccine manufacturer Valneva for the supply of extensive pharmaceutical logistics services. ...

The participating NIPTE team will primarily focus on biopharmaceutical formulations and product development, and FDA regulatory science.

Study is exploring potential benefits of combining a cancer vaccine and PD-1 checkpoint inhibitor.

BioNet's vaccine is the first recombinant monovalent Pertussis vaccine in the world to receive a MAA for booster indication in adolescents and adults.

Investigation reveals improper expense reimbursements.

Ocrevus is the first and only investigational medicine to show superior efficacy versus comparators in both relapsing and primary progressive multiple sclerosis in clinical studies.

New FDA-approved indications for Adynovate provides more hemophilia A patients access to proven prophylaxis with a simple, twice-weekly dosing schedule.

Six patients have been identified with hepatotoxicity, including several cases of veno-occlusive disease, with four fatal events.

Published study results showed an overall response rate of 69.6% for MYL-1401O compared to 64% for branded trastuzumab.

Agreement includes the commercialization and development rights to the newly approved EU drug Zavicefta (ceftazidime-avibactam).

Computationally intelligent drug discovery platform receives two Fierce Innovation awards for Biotech Innovation and Best New Product.

Spinraza improved motor function in SMA patients.

Development and licence agreement is for pMDI inhaled triple therapy (VR2076) for asthma and COPD.

Payment resolves the outstanding civil penalty portion of the company's 2012 administrative settlement with this US DEA.

Abdominal pain improved 56% with CR1 300 mcg relative to placebo in Phase IIb trial.

Oral Otezla receives positive NICE recommendation for adults with psoriatic arthritis.

Mr Wilkinson no longer President and CEO and a member of the Board.

European Commission decision confirms Metformin for treatment in type 2 diabetes patients with moderate renal impairment, which will lead to extended treatment access.

Extension is the result of the submission of additional data regarding the commercial manufacturing process of the biologic.

Acquisition adds global portfolio of sterile injectables, robust pipeline, and manufacturing capabilities.

Novartis and Sunovion Pharmaceuticals strike agreement for three COPD treatments.

Caforio will succeed Lamberto Andreotti effective 2 May 2017.

First and only PARP inhibitor in the US indicated t.o treat advanced ovarian cancer patients who have been treated with two or more chemotherapies and who have deleterious germline or somatic BRCA mutations.

Ionis earns $25 million milestone payment.

Key products include Alloderm and Stratticem tissue matrices commonly used in breast reconstruction and abdominal wall surgeries.

The agreement also provides an option to have Lonza exclusively supply API for up to 20 years.

Acquisition of Encore Vision, to add first-in-class disease modifying topical treatment for presbyopia patients to the Novartis ophthalmology pipeline in an area of high unmet medical need and high prevalence